Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis?

Ultrasound Med Biol. 2011 Dec;37(12):1963-9. doi: 10.1016/j.ultrasmedbio.2011.09.010. Epub 2011 Oct 26.

Abstract

Previously published data suggest a hepatic vein transit time (HVTT) threshold of more than 24 s can distinguish mild to moderate from advanced fibrosis. In this study, we attempted to validate HVTT as a noninvasive index of hepatic fibrosis. Patients were scanned using real-time, pulse-inversion mode following bolus injections of the contrast agent Definity. HVTT was correlated with the degree of fibrosis obtained from contemporaneous liver biopsy. The study population included 40 patients with chronic liver disease and five healthy volunteers. Mean HVTT correlated with histologic grade as follows: absence/minimal fibrosis (n = 18), 25.6 ± 11.8 s; moderate fibrosis (n = 17), 21.5 ± 5.9 s; and severe fibrosis (n = 8), 20.9 ± 5.5 s, (p = .615). Poor sensitivity (57%) and specificity (43%) prevent validation of the previously published HVTT threshold as a surrogate marker of hepatic fibrosis. Further work investigating the different interaction of Definity, SonoVue and Levovist with the reticulo-endothelial system may help explain the discrepant results reported here.

MeSH terms

  • Adult
  • Aged
  • Computer Simulation
  • Contrast Media / pharmacokinetics
  • Female
  • Fluorocarbons / pharmacokinetics*
  • Hepatic Veins / diagnostic imaging
  • Hepatic Veins / metabolism*
  • Humans
  • Image Enhancement / methods
  • Image Interpretation, Computer-Assisted / methods*
  • Liver Cirrhosis / diagnostic imaging*
  • Liver Cirrhosis / metabolism*
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Models, Biological
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Ultrasonography / methods*

Substances

  • Contrast Media
  • Fluorocarbons
  • perflutren